Can-Fite Biopharma Profit Margin

Can-Fite Biopharma's profit margin stands at -24.27% as of December 2025. That compares with -11.69% in the prior-year period — down 107.6% year over year. That is below the Healthcare sector average of 15.58%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Can-Fite Biopharma reported -24.27% in profit margin versus -11.69% a year earlier — a 107.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Can-Fite Biopharma sits lower the Healthcare benchmark (15.58%) with a profit margin of -24.27%. That is roughly 15671.5% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -24.27% for Can-Fite Biopharma means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Can-Fite Biopharma's profit margin evolved across reporting periods, while the comparison chart places CANF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.